908 Devices, a Boston, MA-based developer of analytical devices for chemical and biomolecule analysis, closed $20m in growth equity funding.
Backers included Tao Capital Partners, Cormorant Asset Management, Saudi Aramco Energy Ventures (SAEV), ARCH Venture Partners, Razor’s Edge Ventures, Schlumberger, and Casdin Capital.
The company plans to use the capital to accelerate penetration into established markets for its devices and continue to develop products.
Led by Dr. Kevin J. Knopp, President and CEO, 908 Devices develops point-of-need chemical analysis and biomolecule analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices, serving a range of industries, including safety & security, oil & gas, life sciences and other applied markets.
FinSMEs
15/03/2017